Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3)

被引:59
作者
Borchard, G [1 ]
Cassará, ML [1 ]
Roemelé, PEH [1 ]
Florea, BI [1 ]
Junginger, HE [1 ]
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Pharmaceut Technol, NL-2300 RA Leiden, Netherlands
关键词
budesonide; fluticasone propionate; glucocorticosteroids; Calu-3; bronchial epithelium; drug transport; metabolism;
D O I
10.1002/jps.10151
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Calu-3 cells grown on microporous filters at an air interface for 16-18 days were incubated with the glucocorticosteroid (GCS) budesonide (BUD). Apparent permeability (P-app) of BUD across Calu-3 cell monolayers was determined. Amount of BUD transported across Calu-3 cells was clearly concentration dependent, and no polarised transport was detected. When cells were loaded with BUD by incubation with drug solution (30 muM) for 2 h, 9.35 +/- 0.53% of the initial dose of BUD, corresponding to 5.5 mug BUD/mg cell protein was retained intracellularly, and released over a time period of 10 h. Apical release of BUD was significantly higher than release to the basolateral side of the monolayer. In comparison, when Calu-3 cells were loaded with fluticasone propionate (FP) solution (0.8 muM), about 20% of the initial dose of FP, corresponding to 0.3 mug FP/mg total cell protein content was detected intracellularly and released immediately (45 min). There was no difference in FP release between the apical and basolateral side of the cell layer. Mass spectrometry of cell extracts indicated the presence of fatty acid conjugates of BUD. We conclude that Calu-3 cells are able to store BUD by intracellular conjugation to fatty acids. We, therefore, suggest the use of the Calu-3 cell model as a tool for examination of local pharmacokinetics and metabolism of GCS at the bronchial epithelium. (C) 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:1561-1567, 2002.
引用
收藏
页码:1561 / 1567
页数:7
相关论文
共 23 条
[1]   Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells [J].
Bandi, N ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 425 (02) :109-116
[2]  
BRATTSAND RL, 1986, Patent No. 0170642
[3]   Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells [J].
Cavet, ME ;
West, M ;
Simmons, NL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) :2693-2698
[4]   Biotransformation in vitro of the 22R and 22S epimers of budesonide by human liver, bronchus, colonic mucosa and skin [J].
Cortijo, J ;
Urbieta, E ;
Bort, R ;
Castell, JV ;
Ruiz-Bravo, C ;
Martinez, J ;
Palacios-Pelaez, R ;
Lledó, S ;
Morcillo, EJ .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 (01) :47-54
[5]   Pharmacokinetics and pharmacodynamics of inhaled corticosteroids [J].
Derendorf, H ;
Hochhaus, G ;
Meibohm, B ;
Möllmann, H ;
Barth, J .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (04) :S440-S446
[6]   Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3) [J].
Florea, BI ;
van der Sandt, ICJ ;
Schrier, SM ;
Kooiman, K ;
Deryckere, K ;
de Boer, AG ;
Junginger, HE ;
Borchard, G .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (07) :1555-1563
[7]   127 CULTURED HUMAN TUMOR-CELL LINES PRODUCING TUMORS IN NUDE MICE [J].
FOGH, J ;
FOGH, JM ;
ORFEO, T .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 59 (01) :221-226
[8]  
Forbes Ben, 2000, Pharmaceutical Science and Technology Today, V3, P18, DOI 10.1016/S1461-5347(99)00231-X
[9]   Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery [J].
Foster, KA ;
Avery, ML ;
Yazdanian, M ;
Audus, KL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 208 (1-2) :1-11
[10]  
Hamilton KO, 2001, J PHARM SCI-US, V90, P647, DOI 10.1002/1520-6017(200105)90:5<647::AID-JPS1021>3.0.CO